T1	Participants 251 271	patients with cancer
T2	Participants 427 463	opioid-tolerant patients with cancer
T3	Participants 580 652	opioid-tolerant male and female patients (aged > or =17 years) with BTcP
T4	Participants 1412 1511	131 patients entered the titration phase, of whom 61 were included in the primary efficacy analysis
T5	Participants 2546 2582	opioid-tolerant patients with cancer
